Maryland Stem Cell Research Fund (MSCRF)

What Maryland Stem Cell Research Fund (MSCRF) does

Maryland Stem Cell Research Fund (MSCRF) is a state-funded grant-making program established in 2006 under the Maryland Stem Cell Research Act and administered as an independent program within TEDCO (Maryland Technology Development Corporation). Headquartered in Columbia, Maryland with a small administrative staff (1–10 employees), MSCRF awards non-dilutive grant capital to Maryland-based academic researchers and companies working on stem cell-based therapies, technologies, and manufacturing. Eligibility is restricted to applicants based in Maryland, with federal laboratories explicitly excluded from certain programs.

The Fund operates seven distinct grant programs that span the full innovation pipeline: Discovery (faculty innovative ideas), Post-Doctoral Fellowship, Launch (new or new-to-the-field faculty), Validation (intellectual property needing additional validation), Commercialization (start-up and established companies developing stem cell products), Clinical (human stem cell-based clinical trials requiring a 1:1 non-state match and an IND filing), and Manufacturing Assistance (GMP production support, also requiring a 1:1 match). Decisions are made by the Maryland Stem Cell Research Commission, while TEDCO provides administrative infrastructure, communications, and operational support, including shared leadership such as Executive Director Ruchika Nijhara.

Commercially, MSCRF does not sell products or generate revenue from services. The organization is funded through annual state appropriations — $20.5 million for both fiscal year 2024 and fiscal year 2025 — and deploys that capital via competitive Requests for Applications reviewed by the Commission. Since inception, MSCRF has invested close to $250 million across 750+ projects, supporting work on 32 medical conditions and sustaining a portfolio that includes Reprocell USA, Vita Therapeutics, Theradaptive, RenOVAtE Biosciences, Domicell, RoosterBio, Caring Cross, Caleo Biotechnologies, and others. The Fund reports $525 million in cumulative economic activity and 2,000+ jobs created statewide as of fiscal year 2025.

Name

Maryland Stem Cell Research Fund (MSCRF)

Legal name

Maryland Stem Cell Research Fund

Website

https://mscrf.org

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

1–10 employees

Short description

Maryland Stem Cell Research Fund (MSCRF) is a state-funded grant program under TEDCO that awards non-dilutive funding across seven programs to Maryland-based academic researchers and stem cell companies, supporting the full pipeline from discovery through GMP manufacturing.

Ownership category

akta.pro rank

Product category

Government Stem Cell Research Grants

NAICS

Grantmaking Foundations (813211)

SIC

Services-Engineering, Accounting, Research, Management (8700)

akta.pro primary industry

Health & Medical Research Grantmaking Foundations (BPAGAKAL)

akta.pro secondary industry

Research & Science Grantmaking Foundations (BPAGAKAI)

Keywords

• Stem cell research grants
• Regenerative medicine funding
• Translational research awards
• Biomedical commercialization grants
• State research programs

Headquarters

HQ city

Columbia

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Distribution channels1 record

Marketing channels7 records

Core offering

MSCRF is a state-funded grant-making program that provides non-dilutive financial awards to Maryland-based academic researchers and companies developing human stem cell-based therapies, technologies, and manufacturing capabilities. It administers seven distinct grant programs — Discovery, Post-Doctoral Fellowship, Launch, Validation, Commercialization, Clinical, and Manufacturing Assistance — that together cover the full innovation lifecycle from early-stage research through GMP manufacturing. The fund is operated as an independent program within TEDCO under the Maryland Stem Cell Research Act of 2006, with $20.5 million in annual appropriations.

Product overview

MSCRF is a state-funded grant program (not a technology product company) that offers seven distinct funding programs to support stem cell and regenerative medicine research across Maryland. The programs span the full innovation pipeline from early-stage Discovery research through Clinical trials, providing financial support to academic researchers and companies. The core funding programs include: Discovery (innovative ideas for novel stem cell technologies), Post-Doctoral Fellowship (support for exceptional fellows), Launch (new faculty in regenerative medicine), Validation (technology validation before startup creation), Commercialization (companies developing stem cell products), Clinical (human stem cell-based clinical trials), and Manufacturing Assistance (GMP production support).

Differentiator

Problem solved

Functional benefit

Products and services

• Discovery Grant Program Merit-based grant program providing funding to faculty at Maryland-based universities and research institutes to develop novel human stem cell-based technologies and cures targeting medical conditions such as cancer, diabetes, Parkinson's, and cardiovascular disorders. Federal labs are ineligible.
• Post-Doctoral Fellowship Grant Program Funding program supporting exceptional post-doctoral fellows conducting human stem cell research in academia or industry in Maryland; applicants must have completed their doctoral degree within the past three years.
• Launch Grant Program Awards for new faculty (within five years) or researchers new to the field of human stem cell research at Maryland-based institutions, to encourage independent research programs in regenerative medicine.
• Validation Grant Program Funding for faculty at Maryland-based institutions whose intellectual property for human stem cell-based technologies requires additional validation before the creation of a start-up company.
• Commercialization Grant Program Funding for start-up or established Maryland-based companies developing new human stem cell-based products, supporting activities such as prototype development, IND-enabling studies, and commercial readiness.
• Clinical Grant Program Funding for Maryland-based companies, universities, or research institutes conducting human stem cell-based clinical trials; award requires a 1:1 match of non-state money and an active IND filing.
• Manufacturing Assistance Grant Program Funding for Maryland-based organizations advancing GMP production of stem cell therapy products, including cGMP suite build-out and qualification; requires a 1:1 match of non-state money. First awards were issued in FY2023.

Quantifiable outcome

• Has invested close to $250 million in stem cell research since 2006
• +3 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

25 partnerships are on record, tiered core, major, supporting and emerging.

• TEDCO (Maryland Technology Development Corporation)coreStrategic or Co-development Partner · 1 January 2006MSCRF is an independent program established within TEDCO under the Maryland Stem Cell Research Act of 2006. TEDCO serves as the administrative agent for MSCRF, providing operational infrastructure, staff support (including Executive Director Ruchika Nijhara), meeting coordination, and communications. The Commission functions in conjunction with TEDCO while maintaining independent decision-making authority on grant awards.
• Maryland Department of CommercecoreStrategic or Co-development PartnerCollaboration with Maryland Department of Commerce for events such as the annual Tech Showcase. The Department supports the life sciences community and provides programs like Biotechnology Investor Inventive Tax Credit. Ulyana Desiderio, Senior Director of Office of Strategic Industries and Entrepreneurship, participates in MSCRF events.
• Johns Hopkins UniversitycoreStrategic or Co-development PartnerMajor recipient of MSCRF funding; Johns Hopkins researchers have received numerous Discovery, Launch, Clinical, and other MSCRF awards. The institution represents one of Maryland's premier research universities and a key ecosystem partner in stem cell research.
• University of Maryland, BaltimorecoreStrategic or Co-development PartnerMajor recipient of MSCRF funding; University of Maryland, Baltimore researchers have received numerous Discovery, Launch, Validation, and other MSCRF awards across various medical conditions and diseases.
• University of Maryland, College ParkmajorStrategic or Co-development PartnerAcademic research partner receiving MSCRF funding for stem cell research projects including Discovery and Launch awards.
• Lieber Institute for Brain DevelopmentmajorStrategic or Co-development PartnerMaryland-based research institute receiving MSCRF awards for brain development and neurological disorder research using stem cell technologies.
• Hugo W. Moser Research Institute at Kennedy KriegermajorStrategic or Co-development PartnerMaryland-based research institute receiving MSCRF awards for stem cell research, including Launch awards for researchers new to the field.
• The Geneva FoundationsupportingStrategic or Co-development PartnerResearch foundation receiving MSCRF awards (e.g., Dr. Roopa Biswas received Launch award) for stem cell research projects.
• University of Maryland, Eastern ShoreemergingStrategic or Co-development PartnerNewly represented among MSCRF-funded institutions in FY2025, strengthening statewide support for regenerative medicine research.
• Henry Jackson FoundationsupportingStrategic or Co-development PartnerResearch foundation (affiliated with Uniformed Services University of Health Sciences) receiving MSCRF awards including Discovery awards for stem cell research.
• Alliance for Regenerative MedicinemajorStrategic or Co-development PartnerMichael Lehmicke, Senior VP at Alliance for Regenerative Medicine, delivered keynote address at MSCRF's 2025 Tech Showcase, highlighting the field's promising future and importance of public-private partnerships.
• Reprocell USAcoreStrategic or Co-development PartnerPortfolio company that has received multiple Commercialization and Manufacturing Assistance awards. Current project (2026): 'Generation of Hypoimmune iPSC Seed Stocks for Clinical Applications' and 'Enhancement of Capabilities of Existing Cytocentric Xvivo System Model 2 from BioSpherix'
• Vita TherapeuticscoreStrategic or Co-development PartnerPortfolio company formed in 2018 out of Johns Hopkins; received Commercialization and Manufacturing Assistance awards. Developing iPSC-derived satellite cells for muscular dystrophy therapy; preparing IND for lead therapy.
• Theradaptive, Inc.coreStrategic or Co-development PartnerPortfolio company receiving Commercialization and Clinical awards. OASIS clinical investigation for OsteoAdapt SP in spinal fusion. Dr. Luis Alvarez serves as principal investigator on multiple MSCRF grants.
• RenOVAtE Biosciences, Inc.coreStrategic or Co-development PartnerPortfolio company founded in 2016, performing precision genome editing in livestock species with expansion into biomedical/regenerative medicine applications. Received Commercialization award for 'Growing Human Liver in Pigs' project.
• Domicell, Inc.coreStrategic or Co-development PartnerPortfolio company founded by Johns Hopkins scientists developing the Stem Cell Implantable Bioreactor (SCIB) for heart disease treatment. Received Commercialization award for engineered stem cell products development.
• RoosterBio, Inc.coreStrategic or Co-development PartnerPortfolio company receiving Manufacturing Assistance award for development of closed extracellular vesicle (EV)/exosome drug substance/product manufacturing process.
• Caring CrosscoreStrategic or Co-development PartnerPortfolio company receiving Manufacturing Assistance award for mobile cleanroom-based manufacturing of genetically engineered cellular products.
• Caleo Biotechnologies, Inc.majorStrategic or Co-development PartnerPortfolio company receiving Commercialization award for advancing patient-derived organ-dish platforms for precision therapy in inflammatory bowel disease.
• SereNeuro TherapeuticsmajorStrategic or Co-development PartnerPortfolio company receiving Commercialization award for SN101 Cell Therapy for osteoarthritis pain and commercialization of in vivo pain-relieving human pain-sensing neurons.
• Seraxis, Inc.majorStrategic or Co-development PartnerPortfolio company receiving Manufacturing Assistance award for design, build, and qualification of stem cell manufacturing cGMP suite, and Clinical award for universal cure for insulin-requiring diabetes.
• Agnos Therapeutics, Inc.supportingStrategic or Co-development PartnerPortfolio company receiving Commercialization award for development of Cellular Component Transfer (CCT) as treatment to restore vision in retinitis pigmentosa.
• HOH Cells, LLCsupportingStrategic or Co-development PartnerPortfolio company receiving Commercialization award for development of devices for 3D culture and banking of human iPSCs with high viability and function.
• Britecyte, Inc.supportingStrategic or Co-development PartnerPortfolio company receiving Clinical award for Phase 1/2a study of BRC-OA human adipose allograft for knee osteoarthritis treatment.
• Diagnostic Biochips, Inc.supportingStrategic or Co-development PartnerPortfolio company receiving Commercialization award for high-throughput instrument for neurological and psychiatric drug screening using iPSC-derived 3D cultures.

Scale indicators12 records

Recent moves6 records

Expansion highlights5 records

Market position

Strengths5 records

Weaknesses3 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xtwitter.com/md_stem_cell
• YouTubeyoutube.com/channel/UCaDNVBWF41H0g3t-WJGIxrQ
• LinkedInlinkedin.com/company/mscrf

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments25 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Maryland Stem Cell Research Fund (MSCRF)